Gynecologic Cancer clinical trials at UCSF
1 research study open to eligible people
Gynecologic cancer is cancer in the female reproductive system. UCSF has a clinical trial for PY159, a new treatment for advanced solid tumors. The trial is for patients with tumors that cannot be removed or have come back despite previous treatment. PY159 may be used alone or with another drug called Pembrolizumab.
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
open to eligible people ages 18 years and up
This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).
San Francisco, California and other locations